Glucuronyl Transferase Deficiency Treatment & Management
- Author: Dena Nazer, MD; Chief Editor: Carmen Cuffari, MD more...
Medical Care
Treatment of patients with Crigler-Najjar (CN) syndrome is not limited to phototherapy, phenobarbital therapy, or both. Response to treatment varies according to the type of Crigler-Najjar syndrome.
Crigler-Najjar syndrome type 1 does not respond to phenobarbital therapy, and patients may require repeated exchange transfusions followed by long-term phototherapy to prevent neurologic complications. Other therapies include plasmapheresis, hemoperfusion, cholestyramine, calcium phosphate, and oral agar. An approach to therapy using Sn-protoporphyrin, a heme oxygenase inhibitor, was introduced to prevent an increase in serum bilirubin levels.[8] In patients with Crigler-Najjar syndrome type 1, liver transplantation remains the only guaranteed form of therapy.
In contrast, Crigler-Najjar syndrome type 2 responds favorably to phenobarbital therapy. A favorable response to phenobarbital supports the diagnosis of Crigler-Najjar syndrome type 2. However, rarely, patients with Crigler-Najjar syndrome type 2 may require exchange transfusions or long-term phototherapy.
- Phototherapy
- Phototherapy has been successful in controlling bilirubin levels for years.
- Phototherapy causes the formation of water-soluble bilirubin isomers that can be secreted in bile without conjugation.
- Patients with Crigler-Najjar syndrome type 1 generally need 10-16 hours of treatment per day. Monitor the intensity of light to a level of at least 4-10 µW/cm2/nm. The appropriate wave length is in the blue-green spectrum at 425-475 nm.
- The efficacy of phototherapy is dose dependent; therefore, the response to phototherapy increases when the dose is increased. Efficacy of phototherapy can be increased by increasing the intensity of light, by increasing exposure of body surface, and by using reflecting surfaces (eg, mirrors).
- Double-surface phototherapy has also been used in some cases to improve the outcome.
- The effectiveness of phototherapy decreases with increasing patient age, and the need for alternative therapy increases.
- Newer methods of delivering phototherapy, such as sit-up phototherapy units, may reduce phototherapy time by 50% while maintaining effectiveness and, thus, may allow a child to attend school.
- Long-term phototherapy may lead to developmental delay, impaired weight gain, and possible psychological disturbances.
- Problems associated with phototherapy include decreased effectiveness with age, restriction of activity and play, poor compliance, inability of the patient to travel or take vacations, irritation from the eye shades, difficulties in temperature maintenance, tanning of the skin, embarrassment from the need to be nearly nude during phototherapy, and difficulty in procuring phototherapy lamps.
- Exchange transfusion
- Exchange transfusion is used in Crigler-Najjar syndrome type 1 to lower unconjugated bilirubin levels to a safe level to prevent kernicterus.
- Treatment with exchange transfusions and phototherapy should be intensified early to prevent kernicterus due to high levels of unconjugated bilirubin.
- Gene therapy[9]
- Gene therapy offers the greatest potential for cure for patients with Crigler-Najjar syndrome. Successful cloning of the gene responsible for bilirubin glucuronosyltransferase activity offers the hope of future gene therapy to correct this deficiency.
- Clinically significant improvement can be achieved, even with partial enzyme replacement.
- Only about 5% of normal uridinediphosphoglucuronate glucuronosyltransferase (UGT) 1A1 can significantly lower the plasma bilirubin concentration and decrease the need for phototherapy.
- Studies of the Gunn rat (deficient in all members of the UGT 1A family) showed long-term correction of hyperbilirubinemia with one injection of helper-dependent adenoviral vectors.[5] This effect has yet to be proven in humans.
Surgical Care
- Liver transplantation
- Liver transplantation remains the sole definitive treatment.[10, 11] Cadaveric orthotopic or auxiliary and living related liver transplantation has resulted in excellent survival rates and prognoses.
- Patients with Crigler-Najjar syndrome type 1 are ideal candidates for auxiliary liver transplantation.
- Early liver transplantation in patients with Crigler-Najjar syndrome type 1 decreases the incidence of neurologic deficits, especially for patients in whom reliable administration of phototherapy cannot be guaranteed.
- Hepatocyte transplantation[12, 13, 14]
- Hepatocyte transplantation involves catheterization of the portal vein and an infusion of donor hepatocytes.
- The immunosuppression regimen is similar to that administered to patients receiving whole-organ transplantation and currently includes tacrolimus and prednisolone.
- Stem cells and stem cell–derived hepatocytes should offer the potential to overcome the current limitations of both the supply of hepatocytes and the extent of repopulation of the liver after transplantation.[15]
- Hepatocyte transplantation has been reported to decrease the need for phototherapy and to increase the activity of UGT to 5.5% of normal.
Lucey JF, Suresh GK, Kappas A. Crigler-Najjar syndrome, 1952-2000: learning from parents and patients about a very rare disease and using the internet to recruit patients for studies. Pediatrics. May 2000;105(5):1152-3. [Medline]. [Full Text].
Nydegger A, Bednarz A, Hardikar W. Use of daytime phototherapy for Crigler-Najjar disease. J Paediatr Child Health. Jul 2005;41(7):387-9. [Medline].
Morioka D, Kasahara M, Takada Y, et al. Living donor liver transplantation for pediatric patients with inheritable metabolic disorders. Am J Transplant. Nov 2005;5(11):2754-63. [Medline].
Bosma PJ, Chowdhury NR, Goldhoorn BG, et al. Sequence of exons and the flanking regions of human bilirubin-UDP- glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. Hepatology. May 1992;15(5):941-7. [Medline].
Toietta G, Mane VP, Norona WS, et al. Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A. Mar 15 2005;102(11):3930-5. [Medline].
Jansen PL. Diagnosis and management of Crigler-Najjar syndrome. Eur J Pediatr. Dec 1999;158 Suppl 2:S89-94. [Medline].
Kaplan M, Hammerman C, Maisels MJ. Bilirubin genetics for the nongeneticist: hereditary defects of neonatal bilirubin conjugation. Pediatrics. Apr 2003;111(4 Pt 1):886-93. [Medline].
Sisson TR, Drummond GS, Samonte D, Calabio R, Kappas A. Sn-protoporphyrin blocks the increase in serum bilirubin levels that develops postnatally in homozygous Gunn rats. J Exp Med. Mar 1 1988;167(3):1247-52. [Medline].
Birraux J, Menzel O, Wildhaber B, Jond C, Nguyen TH, Chardot C. A step toward liver gene therapy: efficient correction of the genetic defect of hepatocytes isolated from a patient with Crigler-Najjar syndrome type 1 with lentiviral vectors. Transplantation. Apr 15 2009;87(7):1006-12. [Medline].
Schauer R, Stangl M, Lang T, et al. Treatment of Crigler-Najjar type 1 disease: relevance of early liver transplantation. J Pediatr Surg. Aug 2003;38(8):1227-31. [Medline].
van der Veere CN, Sinaasappel M, McDonagh AF, et al. Current therapy for Crigler-Najjar syndrome type 1: report of a world registry. Hepatology. Aug 1996;24(2):311-5. [Medline].
Ambrosino G, Varotto S, Strom SC, et al. Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1. Cell Transplant. 2005;14(2-3):151-7. [Medline].
Fox IJ, Chowdhury JR. Hepatocyte transplantation. Am J Transplant. 2004;4 Suppl 6:7-13. [Medline].
Lysy PA, Najimi M, Stephenne X, Bourgois A, Smets F, Sokal EM. Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives. World J Gastroenterol. Jun 14 2008;14(22):3464-70. [Medline].
Dhawan A, Mitry RR, Hughes RD. Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis. Apr-Jun 2006;29(2-3):431-5. [Medline].
Nazer H, Al-Mehaidib A, Shabib S, Ali MA. Crigler-Najjar syndrome in Saudi Arabia. Am J Med Genet. Aug 27 1998;79(1):12-5. [Medline].
Ciotti M, Werlin SL, Owens IS. Delayed response to phenobarbital treatment of a Crigler-Najjar type II patient with partially inactivating missense mutations in the bilirubin UDP-glucuronosyltransferase gene. J Pediatr Gastroenterol Nutr. Feb 1999;28(2):210-3. [Medline].
Costa E, Vieira E, Martins M, Saraiva J, Cancela E, Costa M. Analysis of the UDP-glucuronosyltransferase gene in Portuguese patients with a clinical diagnosis of Gilbert and Crigler-Najjar syndromes. Blood Cells Mol Dis. Jan-Feb 2006;36(1):91-7. [Medline].
Miranda PS, Bosma PJ. Towards liver-directed gene therapy for crigler-najjar syndrome. Curr Gene Ther. Apr 2009;9(2):72-82. [Medline].
Nazer H, Gunasekaran TS, Sakati NA, Nyhan WL. Concurrence of Robinow syndrome and Crigler-Najar syndrome in two offspring of first cousins. Am J Med Genet. Dec 1990;37(4):516-8. [Medline].
Strauss KA, Robinson DL, Vreman HJ, Puffenberger EG, Hart G, Morton DH. Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease. Eur J Pediatr. May 2006;165(5):306-19. [Medline].
Vitek L, Muchova L, Zelenka J, et al. The effect of zinc salts on serum bilirubin levels in hyperbilirubinemic rats. J Pediatr Gastroenterol Nutr. Feb 2005;40(2):135-40. [Medline].

